A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects
Phase 2
Completed
- Conditions
- Infection, Human Immunodeficiency VirusHIV Infections
- Interventions
- Drug: CAB Oral TabletsOther: HAARTDrug: ABC/3TC Oral tabletsDrug: RPVDrug: RPV Oral Tablets
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 309
- Registration Number
- NCT02120352
- Locations
- πͺπΈ
GSK Investigational Site, Madrid, Spain
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
Phase 3
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Drug: ABC/DTG/3TC FDCDrug: Ongoing cART regimen
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 555
- Registration Number
- NCT02105987
- Locations
- π΅π·
GSK Investigational Site, San Juan, Puerto Rico
Relative Bioavailability Study With BMS-955176
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 47
- Registration Number
- NCT02095886
- Locations
- π¬π§
GSK Investigational Site, Nottingham, United Kingdom
Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects
- First Posted Date
- 2014-03-10
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 12
- Registration Number
- NCT02082808
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection
Phase 3
Completed
- Conditions
- Infection, Human Immunodeficiency VirusHIV InfectionsArthralgia
- Interventions
- Drug: DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 4
- Registration Number
- NCT02075593
- Locations
- πͺπΈ
GSK Investigational Site, Madrid, Spain
Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)
Phase 2
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 127
- Registration Number
- NCT02076178
- Locations
- πΊπΈ
GSK Investigational Site, Newport News, Virginia, United States
A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 411
- Registration Number
- NCT02076386
- Locations
- π©πͺ
GSK Investigational Site, Weimar, Germany
Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 30
- Registration Number
- NCT02064374
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 42
- Registration Number
- NCT02063360
A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Drug: GSK1265744 Reference formulationDrug: GSK1265744 New formulation 2Drug: GSK1265744 New formulation 1
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 24
- Registration Number
- NCT02059031
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
Β© Copyright 2025. All Rights Reserved by MedPath